BPC-157 Dosing & Reconstitution Guide
Dosing Protocol
Route: Subcutaneous (preferred), Intramuscular, or Oral Frequency: Once daily Dose Range: 200–600 mcg/day SC; oral doses studied at 1–6 mg in clinical trials Cycle Length: 8–12 weeks; optional extension to 16 weeks Timing: Any consistent time daily; inject near site of injury when possible
Reconstitution
Vial Size: 5mg Water Volume: 3mL Concentration: 1.67mg/mL
Titration Schedule
Weeks 1–2: 200 mcg (12 units) Weeks 3–4: 400 mcg (24 units) Weeks 5–8+: 600 mcg (36 units)
Timeline & Pharmacokinetics
Onset: 15–30 minutes (subcutaneous) Peak Plasma: 1–2 hours Half-Life: ~15 min IV (animal data) Steady State: 3–5 days of daily dosing Time to Results: 1–2 weeks for pain reduction; 4–8 weeks for tissue repair Washout: 1–2 weeks
Storage
Lyophilized: −20 °C (−4 °F), dry, dark conditions Reconstituted: 2–8 °C (35.6–46.4 °F), protected from light; avoid freeze-thaw Shelf Life: 28 days
Injection Sites
Abdomen, Thighs, Upper arms, Near injury site
Safety & Contraindications
Safety: No completed randomized controlled human clinical trials for safety assessment Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology FDA previously classified BPC-157 as Category 2 (significant safety concerns); removed from Category 2 on April 15, 2026. PCAC review pending July 2026 to determine compounding eligibility. FDA noted insufficient human safety data and potential immunogenicity risks.
Contraindications: Pregnancy and breastfeeding (no safety data); Active cancer or history of cancer (theoretical concern due to potent angiogenesis promotion; mechanistic overlap with tumor vascularization); Individuals on anticoagulants (BPC-157 affects clotting and vessel constriction resolution)
Related Products
Related Research News
BPC-157 Gut Health: Gastric Cytoprotection Studies
Research on BPC-157 began with gastric cytoprotection in the early 1990s, led by Sikiric and colleagues at the University of Zagreb. Studies show it protects against ethanol-induced lesions and NSAID damage in rat models, with effects linked to angiogenesis, prostaglandins, nitric oxide, and gut-brain signaling. This body of work highlights its stability for oral use and broad preclinical applications in GI models.
BPC-157 Shelf Life: Lyophilized vs Reconstituted Stability Guide
BPC-157 has a finite shelf life that varies by form and storage. Lyophilized powder lasts 12-18 months refrigerated or 24+ months frozen, while reconstituted solution holds for about 28 days under refrigeration. Factors like temperature, light, and handling influence stability, and researchers should watch for signs of degradation to ensure reliable results.
BPC-157 + TB-500 Peptide Blend: Research on Healing and Repair
The BPC-157 and TB-500 peptide blend draws attention in research for potential synergy in tissue repair, angiogenesis, and reducing inflammation. BPC-157, a 15-amino-acid synthetic peptide, interacts with growth factors in preclinical models. TB-500, a 43-amino-acid analog of Thymosin Beta-4, supports cell migration and regeneration. Studies explore their roles in wound healing, tendon recovery, and more.